http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2005516615-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1082 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-32 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 |
| filingDate | 2002-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2005-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2005516615-A |
| titleOfInvention | Methods for identifying novel targets for use in the development of tuberculosis treatments and drugs |
| abstract | A novel target identification method for use in the development of effective treatments and drugs for tuberculosis: (1) Destroy the devR gene present in the insertion site of about 3.3 kb EcoRI-HindIII of plasmid pJT53.34; (2) constructing pJQ200SkdevR :: kan from the disrupted devR gene, (3) introducing the plasmid into M. tuberculosis H37Rv; (4) selecting a single cross-transformant exhibiting plasmid integration on a Middlebrook 7H10 agar plate containing kanamycin; (5) analyzing the cross-transformation by polymerase chain reaction (PCR) for the presence of devR, Km R and sucrose resistance (SacB) gene sequences; (6) The gene sequence is subjected to a Southern analysis step using a devR probe, devS probe, kanamycin resistance gene probe, and M. tuberculosis containing a disrupted copy of the wild type and devR loci. Identify Dup devR, (7) Growing M. tuberculosis Dup devR in Middlebrook 7H9 medium containing kanamycin and sucrose, (8) The grown M. tuberculosis Dup devR strain is put into a plurality of plates having a 7H10 medium containing kanamycin and sucrose to obtain a kanamycin resistant transformant, (9) The grown M. tuberculosis devR is subjected to Southern hybridization, and then the allele exchange is confirmed by polymerase chain reaction. (10) The transformant is subjected to a polymerase chain reaction analysis step to analyze a devR kan disruption gene, (11) The devR kan disrupted gene is subjected to Western blotting and immunoelectron microscopy to confirm functional disruption of the gene, (12) Regarding the devR and devS gene expression, evaluate the viability of M. tuberculosis devR mutant under oxygen-limited conditions, (13) With respect to devR and devS gene expression, the viability of the M. tuberculosis strain devR is evaluated under aerobic oxygen-limited conditions, (14) The grown strain is subjected to a reverse transcription PCR analysis step to obtain a transcript from the Rv3134c-devR-deS operon, (15) The transcript is scanned using a gel recording system manufactured by Ultra-Violet, and further subjected to a densitometer analysis process using computer software. (16) By quantifying the amount of bacteria in the spleen of guinea pigs infected with devR mutants by histopathological analysis of tissues (lung and liver) and microbiological methods, M. tuberculosis (M tuberculosis) The above method comprising testing a devR mutant. |
| priorityDate | 2002-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 563.